Bowen's disease: A six-year retrospective study of treatment with emphasis on resection margins

Acta Dermato-Venereologica

Volumn 94, Issue 4, 2014, Pages 431-435

  Westers Attema, Annet ^a,b   Van Den Heijkant, Fleur ^a   Lohman, Bjorn G P M ^a,b   Nelemans, Patty J ^c   Winnepenninckx, Veronique ^a,b   Kelleners Smeets, Nicole W J ^a,b   Mosterd, Klara ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bowen's disease; Safety margin; Squamous cell carcinoma in situ; Surgical excision

Indexed keywords

FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; BOWEN DISEASE; CANCER SURGERY; CANCER THERAPY; CRYOTHERAPY; DERMATOLOGIST; FEMALE; GENERAL PRACTITIONER; HISTOLOGY; HUMAN; HUMAN TISSUE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHOTODYNAMIC THERAPY; PLASTIC SURGEON; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY MARGIN; SQUAMOUS CELL CARCINOMA; SURGICAL MARGIN; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADULT; BOWEN'S DISEASE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NETHERLANDS; REGISTER; REOPERATION; RISK FACTOR; SKIN NEOPLASMS; SKIN SURGERY; TIME; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; BOWEN'S DISEASE; DERMATOLOGIC SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NETHERLANDS; REGISTRIES; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902764714     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1771     Document Type: Article

References (21)

1. Bowen J. Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J Cutan Dis 1912; 241-255.
2. Arlette JP, Trotter MJ. Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 2004; 45: 1-9.
3. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007; 156: 11-21.
4. Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg 2011; 37: 1394-1411.
5. Venereologie NVvDe. Nederlandse Vereniging voor Dermatologie en Venereologie. Guideline squamous cell carcinoma of the skin, 2010. Available at: http://www.huidarts.info.
6. Kossard S, Rosen R. Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol 1992; 27: 406-410.
7. Council NHaMR. Clinical Practice Guidelines: Nonmelanoma skin cancer: Guidelines for treatment and management in Australia, 2002. Available at: http://www.nhmrc.gov.au/guidelines.
8. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27-34.
9. Clavel CE, Huu VP, Durlach AP, Birembaut PL, Bernard PM, Derancourt CG. Mucosal oncogenic human papillomaviruses and extragenital Bowen disease. Cancer 1999; 86: 282-287.
10. Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J Am Acad Dermatol 2008; 59: 68-71.
11. Kao GF. Carcinoma arising in Bowen's disease. Arch Dermatol 1986; 122: 1124-1126.
12. Szeimies RM, Karrer S, Backer H. Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt 2005; 56: 430-440.
13. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. British Association of Dermatologists. Br J Dermatol 1999; 141: 633-641.
14. Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-1032.
15. Bonerandi JJ, Beauvillain C, Caquant L, Chassagne JF, Chaussade V, Clavere P, et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 2011; 25: 1-51.
16. Network NCC. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Basal cell and squamous cell skin cancers, 2012. Available at: http://www.nccn.org/professionals.
17. Kerns MJ, Darst MA, Olsen TG, Fenster M, Hall P, Grevey S. Shrinkage of cutaneous specimens: formalin or other factors involved? J Cutan Pathol 2008; 35: 1093-1096.
18. Goulding JM, Levine S, Blizard RA, Deroide F, Swale VJ. Dermatological surgery: a comparison of activity and outcomes in primary and secondary care. Br J Dermatol 2009; 161: 110-114.
19. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients - where do we stand today? Am J Transplant 2008; 8: 2192-2198.
20. Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90: 683-687.
21. Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg 2004; 30: 634-641.